MKI-1 MASTL Kinase Inhibitor-1|cas:1190277-80-5|西域试剂

MKI-1 MASTL Kinase Inhibitor-1,98.27%

产品编号：Bellancom-137552| CAS NO：1190277-80-5| 分子式：C₁₈H₁₄N₄O| 分子量：302.33

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-137552	￥3000.00	杭州北京（现货）
Bellancom-137552	￥5000.00	杭州北京（现货）
Bellancom-137552	￥9500.00	杭州北京（现货）
Bellancom-137552	￥15500.00	杭州北京（现货）
Bellancom-137552	￥23500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MKI-1 MASTL Kinase Inhibitor-1

产品介绍

MKI-1 是微管相关丝氨酸/苏氨酸样激酶 (MASTL) 的抑制剂，其IC₅₀ 为9.9 μM。MKI-1 通过激活乳腺癌中的PP2A 发挥抗肿瘤和放射增敏活性。

生物活性

MKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC₅₀ of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer.

体外研究

MKI-1 (5-20 μM) inhibits the activity of MASTL in breast cancer cells.
MKI-1 (100 μM, 72 h) inhibits various oncogenic properties of breast cancer cells but showed much weaker effects on the viability of normal breast cells.
MKI-1 clearly reduces both serine 62-phosphorylation of c-Myc and total c-Myc, with a decrease in ENSA phosphorylation.
MKI-1 (20 μM, 16 h) reduces c-Myc stability through PP2A activation in MCF7 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	MCF7 and T47D cells.
Concentration:	5-20 μM.
Incubation Time:	24 h.
Result:	Inhibited the phosphorylation of ENSA in MCF7 and T47D cells. Significantly inhibited the phosphorylation of ENSA in mitotic cells.

体内研究
(In Vivo)

MKI-1 (50 mg/kg, ip, twice a week) reduces tumor growth and enhances the radiosensitivity of BT549 xenograft model in response to 6 Gy irradiation compared with the control group, with no notable changes in body weight, suggesting the absence of gross toxicity in the treated mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Five-week-old female BALB/c nude mice (BT549 cells).
Dosage:	50 mg/kg.
Administration:	Twice per week by intraperitoneal (i.p.) injection.
Result:	Reduced tumor growth.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Five-week-old female BALB/c nude mice (BT549 cells).
Dosage:	50 mg/kg.
Administration:	Twice per week by intraperitoneal (i.p.) injection.
Result:	Reduced tumor growth.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Five-week-old female BALB/c nude mice (BT549 cells).
Dosage:	50 mg/kg.
Administration:	Twice per week by intraperitoneal (i.p.) injection.
Result:	Reduced tumor growth.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (826.91 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.3076 mL	16.5382 mL	33.0764 mL
5 mM	0.6615 mL	3.3076 mL	6.6153 mL
10 mM	0.3308 mL	1.6538 mL	3.3076 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式